– Renovacor, Inc. has entered into a definitive merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) – – Upon closing, the combined company is expected to receive up to $116 million in proceeds and is expected to be listed on NYSE under the ticker symbol “RCOR” – – […]
Financial
Windtree Therapeutics Announces Pricing of $30.0 Million Public Offering
WARRINGTON, Pa., March 23, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the pricing of its previously announced public offering of 9,230,500 shares of our common stock, par value $0.001 per […]
InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company’s Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of Stockholders
TEL AVIV, Israel, March 22, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today issues a message to stockholders from InspireMD CEO, Marvin Slosman regarding the Company’s Special Meeting of […]
Shockwave Announces Joint Venture in China
Establishes a Company to Maximize the Availability of IVL for the Chinese Population SANTA CLARA, Calif., March 22, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company has signed an […]
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease
Company closes additional $22.6 million in new financing Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as adjunctive therapy for patients undergoing coronary artery bypass graft surgery MALVERN, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for […]
Cardiovascular Systems, Inc. Announces Acquisition of Peripheral Support Catheters From WavePoint Medical, LLC
Agreement also includes development of portfolio of CTO products ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that it has acquired a line of peripheral support catheters from WavePoint Medical, LLC. Peripheral support catheters are used during peripheral vascular intervention (PVI) procedures for guidewire support to enable […]
Evidation Raises $153M to Scale Virtual Health Capabilities of Achievement™ Platform
Funding will be used to launch a range of virtual health programs to make it easier for individuals to manage their health SAN MATEO, Calif.–(BUSINESS WIRE)–Evidation Health today announced the close of $153 million in Series E growth funding to rapidly expand its virtual health programs on AchievementTM, the largest […]
SANUWAVE Health Announces Distribution Agreement with Labb Solutions
SANUWAVE to Distribute dermaPACE® System and UltraMIST® System in Turkey and in Select Eastern Europe and Middle East Countries SUWANEE, GA, March 19, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair […]
JenaValve Technology Welcomes Jane Metcalf as Vice President, Regulatory Affairs and Quality
IRVINE, Calif., March 18, 2021 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated pericardial transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, announces the appointment of Jane Metcalf to Vice President, Regulatory Affairs and Quality, effective immediately. Ms. Metcalf comes to JenaValve […]
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 New patent issued by USPTO for use of Gencaro in treating atrial fibrillation in heart failure patients with ejection fractions greater than 40% WESTMINSTER, Colo., March 18, 2021 […]



